Prada-Delgado O, Estévez-Loureiro R, López-Sainz A, Gargallo-Fernández P, Paniagua-Martín M J, Marzoa-Rivas R, Barge-Caballero E, Cuenca-Castillo J J, Castro-Beiras A, Crespo-Leiro M G
Transplant and Advanced Heart Failure Unit, Division of Cardiology, Complejo Hospitalario Universitario A Coruña, Spain.
Transplant Proc. 2012 Nov;44(9):2657-9. doi: 10.1016/j.transproceed.2012.09.043.
Cardiac allograft vasculopathy (CAV) remains a major impediment to long-term survival after heart transplantation (HT). Limited data exist regarding the impact of coronary revascularization in these patients.
To evaluate the outcomes of revascularization procedures in patients with CAV compared with patients who did not undergo revascularization.
Retrospective analysis of 249 patients who underwent HT at our center between June 1998 and December 2009 and who were examined by coronary angiography after HT. We included patients with moderate or severe CAV according to the International Society for Heart and Lung Transplantation (ISHLT) nomenclature to evaluated outcomes after revascularization or diagnostic angiography. Major adverse cardiovascular events (MACE) comprised death, acute coronary syndrome, coronary revascularization, admission because of heart failure not due to an acute rejection episode, and cardiac retransplantation.
Moderate or severe CAV was detected in 43 patients. Twelve (27.9%) underwent coronary revascularization: eight percutaneous interventions and four bypass surgeries. Indications for revascularization were symptomatic ischemia or noninvasive evidence of ischemia (n = 6, 14.0%) or high-risk asymptomatic CAV (n = 6; 14.0%), namely, lesions located in the left main or proximal anterior descending arteries or multivessel disease with left ventricular dysfunction. The remaining 31 (72.1%), who did not undergo revascularization showed an absence of ischemia during exercise echocardiography (n = 11; 25.6%) or diffuse disease not amenable to revascularization (n = 20; 46.5%). During a mean follow-up of 3.0 ± 2.4 years, MACE occurred in three revascularized patients (25.0%), in one with absence of stress-induced ischemia (9.1%) and in 13 with nonrevascularizable disease (65%; P = .012).
Revascularization procedures were effective in HT patients with evidence of ischemia or high-risk CAV. Patients with absence of stress-induced ischemia have a good prognosis without revascularization. On the other hand, diffuse nonrevascularizable CAV is associated with a poor prognosis.
心脏移植血管病变(CAV)仍然是心脏移植(HT)后长期生存的主要障碍。关于冠状动脉血运重建对这些患者的影响,现有数据有限。
评估CAV患者与未接受血运重建患者的血运重建手术结果。
回顾性分析1998年6月至2009年12月在本中心接受HT且HT后接受冠状动脉造影检查的249例患者。根据国际心肺移植学会(ISHLT)的命名法,纳入中度或重度CAV患者,以评估血运重建或诊断性血管造影后的结果。主要不良心血管事件(MACE)包括死亡、急性冠状动脉综合征、冠状动脉血运重建、因非急性排斥发作导致的心力衰竭入院以及心脏再次移植。
43例患者检测出中度或重度CAV。12例(27.9%)接受了冠状动脉血运重建:8例经皮介入治疗和4例搭桥手术。血运重建的指征为有症状的缺血或缺血的无创证据(n = 6,14.0%)或高危无症状CAV(n = 6;14.0%),即位于左主干或近端前降支动脉的病变或伴有左心室功能障碍的多支血管病变。其余31例(72.1%)未接受血运重建的患者在运动超声心动图检查中未显示缺血(n = 11;25.6%)或存在不适合血运重建的弥漫性病变(n = 20;46.5%)。在平均3.0±2.4年的随访期间,3例接受血运重建的患者(25.0%)、1例无应激性缺血的患者(9.1%)和13例有不可血运重建病变的患者(65%)发生了MACE(P = 0.012)。
血运重建手术对有缺血证据或高危CAV的HT患者有效。无应激性缺血的患者不进行血运重建预后良好。另一方面,弥漫性不可血运重建的CAV与预后不良相关。